NVS
Novartis AG ADR
Novartis AG ADR historical holders
total: 9
Dodge & Cox Stock Fund Novartis AG ADR transactions over time
- Total transactions:
- 20
- New positions:
- 1
- Added:
- 4
- Reduced:
- 15
- Held since:
- 2019 Q3
- Held for:
- 27 quarters
- Latest activity:
- 2026 Q1
Dodge & Cox Stock Fund has been an institutional investor in Novartis AG ADR (NVS) since 2019 Q3. According to 2026 Q1 report, Dodge & Cox Stock Fund holds 5,087,508 shares with a market value of roughly $777.12M representing 0.68% of their equity portfolio. The fund/company first acquired NVS in 2019 Q3, initially purchasing about 17.37M shares. Since the initial investment, Dodge & Cox Stock Fund has made 19 more transactions in this position.
Does Dodge & Cox Stock Fund still hold NVS?
Yes, Dodge & Cox Stock Fund continues to hold Novartis AG ADR (NVS). According to their 2026 Q1 report, they maintain a position of 5,087,508 shares valued at approximately $777.12M, representing 0.68% of their equity portfolio.
When did Dodge & Cox Stock Fund first invest in NVS?
Dodge & Cox Stock Fund first invested in Novartis AG ADR (NVS) in 2019 Q3 at the reported quarter-end price of $86.90 per share, acquiring 17,366,300 shares in their initial purchase.
What is Dodge & Cox Stock Fund's average cost basis for NVS?
Based on historical transaction data, Dodge & Cox Stock Fund's estimated cost basis for Novartis AG ADR (NVS) is approximately $86.38 per share. This represents their average reported price* across all buy transactions.
Estimated cost basis*
- Weighted AVG buy price:
- $86.38
- Weighted AVG sell price:
- $100.76
NVS transactions history by Dodge & Cox Stock Fund
20 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2026 Q1
|
0.68%
|
5,087,508
|
$152.75
|
$777,116,847
|
-25.16% (-1,710,100)
|
-0.22%
|
|
2025 Q4
|
0.78%
|
6,797,608
|
$137.87
|
$937,186,215
|
-16.52% (-1,345,200)
|
-0.15%
|
|
2025 Q2
|
0.84%
|
8,142,808
|
$121.01
|
$985,361,196
|
-10.96% (-1,002,200)
|
-0.11%
|
|
2025 Q1
|
0.90%
|
9,145,008
|
$111.48
|
$1,019,485,492
|
-3.03% (-285,600)
|
-0.03%
|
|
2024 Q4
|
0.82%
|
9,430,608
|
$97.31
|
$917,692,464
|
-0.10% (-9,400)
|
-0%
|
|
2023 Q4
|
0.94%
|
9,440,008
|
$100.97
|
$953,157,608
|
-20.00% (-2,360,300)
|
-0.26%
|
|
2023 Q3
|
1.30%
|
11,800,308
|
$101.86
|
$1,201,979,373
|
-0.18% (-21,200)
|
-0%
|
|
2023 Q2
|
1.29%
|
11,821,508
|
$100.91
|
$1,192,908,372
|
-20.71% (-3,087,692)
|
-0.35%
|
|
2022 Q3
|
1.43%
|
14,909,200
|
$76.01
|
$1,133,248,292
|
-5.01% (-787,000)
|
-0.07%
|
|
2022 Q2
|
1.55%
|
15,696,200
|
$84.53
|
$1,326,799,786
|
-18.91% (-3,660,900)
|
-0.31%
|
|
2021 Q4
|
1.75%
|
$87.47
|
-3.28% (-656,800)
|
|||
|
2021 Q3
|
1.80%
|
$81.78
|
+25.76% (+4,099,244)
|
|||
|
2021 Q2
|
1.63%
|
$91.24
|
+13.25% (+1,862,593)
|
|||
|
2021 Q1
|
1.48%
|
$85.48
|
+1.31% (+182,063)
|
|||
|
2020 Q4
|
1.85%
|
$94.43
|
-0.16% (-22,700)
|
|||
|
2020 Q3
|
1.99%
|
$86.96
|
+13.94% (+1,700,000)
|
|||
|
2020 Q2
|
1.78%
|
$87.34
|
-14.84% (-2,124,100)
|
|||
|
2020 Q1
|
2.29%
|
$82.45
|
-13.97% (-2,324,800)
|
|||
|
2019 Q4
|
2.11%
|
$94.69
|
-4.17% (-724,700)
|
|||
|
2019 Q3
|
2.18%
|
$86.90
|
new
|
|||
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.